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Objectives: The increasing diabetes prevalence and advent of new treatments for its major 
visual-threatening complications (diabetic macular edema [DME] and proliferative diabetic 
retinopathy [PDR]), which require frequent and life- ong follow-up, have markedly increased 
hospital demands.  Resulting delays in the evaluation/treatment of patients are leading to 
sight loss.  Strategies to increase capacity of medical retina clinics are urgently needed.  
EMERALD tested diagnostic accuracy, acceptability and costs of a new health care pathway 
for people with previously treated DME/PDR.   
Design: Prospective, multicentric, case-referent, cross-sectional, diagnostic accuracy study, 
undertaken in 13 hospitals in the United Kingdom.  
Participants: Adults with type 1 or 2 diabetes and previously successfully treated DME/PDR 
who, at the time of enrolment, had active or inactive disease.  
Methods: A new health care pathway entailing multimodal imaging (spectral domain optical 
coherence tomography [SD-OCT] for DME, and 7-field Early Treatment Diabetic 
Retinopathy Study [ETDRS] and ultra-wide-field funds images [UWF] for PDR) interpreted 
by trained non-medical staff (ophthalmic graders) to detect re-activation of disease was 
compared with the current standard care (ophthalmologists face-to-face examination).  
Main outcome measures: Primary outcome: sensitivity of the new pathway. Secondary 
outcomes: specificity; agreement between pathways; costs; acceptability; proportions 
requiring subsequent ophthalmologist assessment, unable to undergo imaging, with 
inadequate images/indeterminate findings.    
Results: The new pathway had sensitivity of 97% (95% confidence interval [CI] 92-99%) 
and specificity of 31% (95% CI 23-40%) to detect DME. For PDR, sensitivity and specificity 
using 7-field ETDRS (85%, 95% CI 77-91%; 48%; 95% CI 41-56%, respectively) or UWF 










of high risk PDR sensitivity and specificity were hig er when using UWF images (87%, 95% 
CI 78-93%; 49% 95% CI 42-56%, respectively for UWF, versus 80%, 95% CI 69-88%; 40% 
CI 34-47%, respectively, for 7-field ETDRS). Participants preferred ophthalmologist’s 
assessments; in their absence, wished immediate feedback by graders, maintaining periodic 
ophthalmologist evaluations. When compared with the current standard care, the new 
pathway could save £1,390/100 DME visits and between £461-£1,189/100 PDR visits. 
Conclusion: The new ophthalmic grader pathway has acceptable sensitivity and would 











Diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) are the major 1 
sight threatening complications of diabetic retinopathy which, in its turn, is the most common 2 
microvascular complication of diabetes.1 DME and PDR are leading causes of sight 3 
impairment and blindness worldwide.2-4 4 
Treatment for DME includes macular laser, intravitreal anti-vascular endothelial 5 
growth factor (anti-VEGF) therapies, and intravitreal steroids.5-14 Macular laser is delivered 6 
in a single session; retreatments may be required and, if so, are usually given at 3-4 month 7 
intervals. Anti-VEGFs are administered monthly until the macula is dry; for the great 8 
majority of patients this is not achieved during the first year of treatment.15  Once DME has 9 
resolved, patients are followed every 3–4 months following macular laser, and monthly 10 
initially, and every 1–4 months thereafter, following anti-VEGFs.16,17  Intravitreal steroids are 11 
given at less frequent intervals than anti-VEGFs but patients receiving them still require close 12 
follow-up as they can lead to an increase in intraocular pressure.10  Independently of the 13 
treatment received, follow-up continues for the rest of the patient’s life as DME may recur 14 
and further treatment required to prevent sight loss.  15 
Laser panretinal photocoagulation (PRP) remains the mainstay therapy for PDR.18 16 
Laser PRP is most often completed in two sessions. Recent trials have shown anti-VEGFs to 17 
be non-inferior to PRP for the treatment of PDR.19,20  Anti-VEGFs, however, do not appear to 18 
be cost-effective when compared with laser, except in atients with concomitant DME.21 19 
Once regression of PDR is noted, patients are followed every 6-12 months for life, as PDR 20 
may also recur. 16   21 
At follow-up appointments, ophthalmologists with exp rtise in retinal diseases 22 
examine the retina by slit-lamp biomicroscopy and determine whether recurrence of DME 23 
and/or PDR is present. Spectral domain optical coherence tomography (SD-OCT) is routinely 24 










high (~7% of all people with diabetes),22,23 given the very high prevalence of diabetes in the 26 
population,24,25 with ~463 million adults worldwide living with diabetes, and the requirement 27 
for patients to be reviewed frequently and for life, as underlined above, diabetic eye disease is 28 
posing major problems of capacity to ophthalmic clini s in many countries, especially due to 29 
shortage of ophthalmologists.26 As a result, patients’  appointments are often delayed, and 30 
treatments are not given timely.  Delays in follow-up appointments in secondary care have 31 
been shown to lead to sight loss, even blindness in people with diabetic retinopathy.27 The 32 
challenge that diabetes poses to health care systems in developed, and specially, developing 33 
countries has been recently highlighted.16  Retinal clinics are further stretched as anti-VEGFs 34 
are used also to treat other diseases, including age-related macular degeneration and retinal 35 
vein occlusion.  Recent cancellations of all routine appointments worldwide during the 36 
COVID19 pandemic have exacerbated this problem to unprecedented levels.  Thus, it is 37 
imperative that new ways to increase efficiency andcapacity of ophthalmic clinics are 38 
identified and, if safe and acceptable, implemented.    39 
EMERALD (Effectiveness of Multimodal imaging for the Evaluation of Retinal 40 
oedema And new vesseLs in Diabetic retinopathy) was conceived with the above purpose. It 41 
tested whether patients with DME and/or PDR previously successfully treated (i.e. DME 42 
cleared and PDR became inactive) could be followed through a new care pathway involving 43 
multimodal retinal imaging assessed by trained non-medical staff (ophthalmic graders). 44 
Diagnostic accuracy, cost-consequences, and acceptability of this new pathway to patients 45 
and healthcare professionals were evaluated against the current standard of care (face-to-face 46 












Institutional Review Board and ethical approvals were obtained for this study prior to its 50 
initiation (reference 17/NI/0124); the study was conducted in accordance with the ethical 51 
principles of the Declaration of Helsinki.  EMERALD was funded by the Health Technology 52 
Assessment of the National Institute for Health Research (NIHR-HTA) in the United 53 
Kingdom (13/142/04). 54 
Patient and Public Involvement  55 
At study conception, a patient and public involvement (PPI) group was established, with the 56 
help of Diabetes UK, Northern Ireland.  Meetings and discussions between EMERALD 57 
researchers and the EMERALD PPI group took place early on, at the planning stages of the 58 
project, to confirm the research question was important and the tests proposed adequate and 59 
feasible to patients. The PPI group provided, in addition, help and input to the elaboration of 60 
participant-related materials for the study and will provide support with the dissemination of 61 
findings. 62 
Study design, setting, participants and recruitment period 63 
EMERALD was designed as a case-referent, cross-sectional, multicentre, diagnostic study 64 
with sampling of patients and data collection carried out prospectively,28 providing a cost-65 
efficient design with low risk of bias in terms of diagnostic accuracy.29 66 
The study was conducted in ophthalmic clinics of 13 National Health Service (NHS) 67 
hospitals across the UK, with sites in England (n=11), Scotland (n=1) and Northern Ireland 68 
(n=1). Eligible participants were adults with diabetes (type 1 or 2) with previously 69 
successfully treated DME/PDR in one/both eyes.  Participants were considered to have been 70 
successfully treated if at their last visit in clinic, no further treatment had been indicated by 71 
the treating ophthalmologists due to lack of activity of PDR/DME. Only participants unable 72 
to speak/understand English and those unable to provide informed consent were excluded.  73 










At the time of enrolment, DME/PDR could be active or inactive.   An ophthalmologist 75 
confirmed eligibility; for those willing to participate, informed consent was obtained prior to 76 
enrolment. Participants were recruited between October 26th 2017 and June 7th 2019. 77 
Clinical pathways assessed and training of ophthalmic graders 78 
New pathway: Ophthalmic grader pathway 79 
The new pathway tested consisted of the review of SD-OCT scans, to detect DME, and 7-80 
field ETDRS and UWF images, to detect PDR, by trained and tested ophthalmic graders (see 81 
below). Ophthalmic graders determined whether there was active or inactive DME/PDR, or 82 
whether they were unsure or unable to grade images, in which case patients would be referred 83 
for an ophthalmologist assessment. If there was no DME/no active PDR, the grader would 84 
arrange a review appointment for the patient in the ophthalmic grader pathway at a pre-85 
determined interval.   86 
Standard of care pathway (reference standard) 87 
The standard of care pathway for DME and PDR was the current standard of care: face-to-88 
face evaluation of patients by ophthalmologists using lit-lamp biomicroscopy and SD-OCT 89 
scans.  Active/Inactive DME/PDR were judged by ophthalmologists based on clinical 90 
examination and, in addition, for DME, findings on SD-OCT. 91 
Enhanced reference standard for PDR 92 
As it is possible that ophthalmologists miss new vessels when evaluating patients by slit-lamp 93 
biomicroscopy, EMERALD included an ‘enhanced’ refernce standard for PDR. This 94 
consisted of the reference standard, as above, supplemented by the evaluation of 7-field 95 
ETDRS and UWF images, both reviewed by an ophthalmologist expert in DR. If active PDR 96 
was detected in one of these three evaluations (slit-lamp biomicroscopy, 7-field ETDRS or 97 
UWF fundus images) it was considered there was active PDR based on the enhanced 98 










Images were taken by trained ophthalmic photographers/imaging technicians at participating 100 
sites. 7-field ETDRS images were obtained using standard fundus cameras available at each 101 
participating site. The Optos system (Optos Inc., Dunfermline, Fife, UK) was used to obtain 102 
UWF images.  103 
 In EMERALD, all participants went through the stand rd of care pathway (i.e. were 104 
reviewed by an ophthalmologist who set the reference standard). SD-OCT scans were 105 
obtained as per standard of care. For the purpose of th  study, 7-field ETDRS and UWF 106 
images were taken to detect PDR in the ophthalmic grader pathway and for the enhanced 107 
reference standard.  108 
Anonymised images were transferred from participating sites to a central facility, then were 109 
randomly assigned to graders and ophthalmologists in the clinical sites. EMERALD used a 110 
commercially available platform (Ophthalsuite, BlueWorks, Coimbra, Portugal) for graders 111 
to see all images on computer screens. 112 
Selection and training of ophthalmic graders was as follows. Firstly, local principal 113 
investigators suggested names of individuals at their sit s with experience obtaining and/or 114 
grading images of patients with DME/PDR.  These individuals were approached to confirm 115 
their interest/willingness to participate in EMERALD. They were asked to fill in a 116 
questionnaire detailing their experience recognising features of DME/PDR; those who stated 117 
they did not have experience and those unwilling to be part of the study were not invited to 118 
participate in EMERALD. 119 
Candidates to be ophthalmic graders then received formal training. During training, which 120 
included a two-day face-to-face meeting and two additional half-day webinar sessions, 121 
features of active/inactive DME/PDR were reviewed an discussed, and extensive clinical 122 
examples were presented. A web-based teaching module with examples of DME/PDR was 123 










guidelines on when patients would need referral to ophthalmologists. The following 125 
definitions for active and inactive DME and PDR were given: 126 
• Active DME was defined as DME with central retinal thickness of > 300 microns on 127 
SD-OCT and/or presence of intraretinal and/or subretinal fluid on SD-OCT due to 128 
DME. Isolated or sparse small intraretinal cysts were not considered DME.  129 
• Inactive DME was defined as no intraretinal/subretinal fluid. 130 
• Active PDR was defined by the presence of sub-hyaloid or vitreous haemorrhage 131 
and/or active new vessels (new vessels with lack of fibrosis on them). 132 
• Inactive PDR was defined by lack of sub-hyaloid or vitreous haemorrhage and lack of 133 
active new vessels.  134 
Following training, ophthalmic graders were required to take a test involving the reading of 135 
SD-OCT, 7-field ETDRS, and UWF images, with and without DME and with and without 136 
active PDR. Those reaching a minimum of 80% of correct answers were invited to take part 137 
in EMERALD. If failing this first test, graders could undergo further training and take a new 138 
test but if the 80% minimum was not attained,30 they were unable to be graders for 139 
EMERALD. 140 
Masking 141 
Ophthalmic graders were masked to the reference standard. To ensure this, they did not 142 
interpret images from patients recruited at their own centre and had no access to results of the 143 
reference standard. They did not read 7-field ETDRS, UWF, and SD-OCT images of the 144 
same eye, to ensure reading of one imaging technology w uld not influence the reading of the 145 
other.  146 
Ophthalmologists doing the standard of care evaluation (i.e. setting the reference standard) 147 
were masked to findings/decisions made by ophthalmic graders (who reviewed images at a 148 










Outcome measures 150 
Primary: Sensitivity of the new pathway to detect DME/active PDR.  151 
Secondary: Specificity, concordance, costs, acceptability of the new pathway to patients and 152 
health care professionals, proportions of patients requiring subsequent assessment by 153 
ophthalmologists, unable to undergo imaging and with images of inadequate quality for 154 
interpretation.  155 
Acceptability of the new pathway to patients and health care professionals 156 
 Focus group discussions were undertaken. Participants were approached and consent 157 
obtained from those willing to participate in focus group discussions at the same time they 158 
were approached to participate in the main diagnostic accuracy study. Ophthalmologists and 159 
ophthalmic photographers/graders were also invited to participate in separate focus group 160 
discussions. Detailed methodology and results of this qualitative part of EMERALD will be 161 
published separately. 162 
Sample size and statistical analysis 163 
The sample size was determined on the basis of setting a target of the number of people with 164 
reactivated (active) DME and PDR required to enable sensitivity to be tested against a pre-165 
specified target level of 80%. The required sample siz was calculated using formula T1 from 166 
Obuschowski 199831 in Microsoft Excel – it was a Wald-test based calculation. This level 167 
was considered the minimum acceptable for the new pathway to be clinically viable. A lower 168 
specificity was considered acceptable; a target of 65% was used to confirm sufficiency of 169 
sample size to assess specificity. Eighty-nine participants with DME/ PDR which had 170 
reactivated (active DME/PDR) was sufficient to detect if the sensitivity of the new pathway is 171 
10% and 12% higher than the 80% minimal target set with 80% and 90% power, respectively 172 
at the 2-sided 5% significance level.32 Ninety-three participants who have not reactivated 173 










confidence interval for the ophthalmic grader pathway sensitivity and specificity would have 175 
a confidence interval (Wilson method) with a width of 10-20% depending on the observed 176 
level.33 Allowing for 10% missing/indeterminate results, 104 individuals who had re-177 
activated and 104 who had not, were required (208 for each, DMEand PDR), leading to a 178 
maximum of 416 participants in the study overall. Because participants could have both DME 179 
and PDR and contribute to both targets, the number of participants required could be lower 180 
than 416.  181 
Separate analyses were planned for DME and PDR. Particip nts were categorised as having 182 
active or inactive DME/PDR according to the reference standard, at the person level. Those 183 
with previously successfully treated DME/PDR constituted ‘eligible’ participants for each 184 
analysis (DME/PDR) for the new pathway. This person-based assessment reflects the 185 
consequences of the clinical decision in clinical pr ctice. The diagnostic performance of the 186 
new pathway was quantified against the reference standard. Reflecting how the new pathway 187 
would function in practice, ‘unsure’, ‘ungradable’ and ‘active’ classifications required 188 
‘referral’ and examination by an ophthalmologist under the main analyses. The impact of 189 
using 7-field ETDRS versus UWF images on the diagnostic performance of the new pathway 190 
was assessed under the principal analyses for PDR using both reference standard and 191 
enhanced reference standard. Agreement between PDR assessment methods was quantified. 192 
Planned sensitivity analyses included 1) assessment of the impact of ‘unsure’ and 193 
‘ungradable’ on the diagnostic performance of the ophthalmic grader; 2) using the 194 
ophthalmologist’s decision that further treatment was required, rather than presence of active 195 
disease; 3) detection of severe disease (central-invo vi g in DME; sub-hyaloid/vitreous 196 
haemorrhage in PDR); 4) diagnostic performance within routine NHS clinics versus 197 
‘research’ clinics, and; 5) for PDR only, diagnostic performance of the ophthalmic grader 198 









Secondary analyses included evaluation of eye leveldata; analysis including all patients 200 
(with/without DME/PDR); assessment of the overall refe ral (for DME and PDR); and use of 201 
visual acuity as a proxy to detect active disease.  Additional, post-hoc analyses were carried 202 
out in the PDR group only to aid understanding findings of pre-planned analyses (see 203 
supplementary Table 4).   204 
The main analysis and sensitivity analysis included only eligible participants for the 205 
particular pathway (for the new DME pathway, people with at least one eye with previously 206 
successfully treated DME; for the new PDR pathway, people with at least one eye with 207 
previously successfully treated PDR).  These participants may have had an “ineligible” eye 208 
but, as these analyses were based on a person level (as this is what will happen in real life if 209 
the pathway is introduced) each of the two eyes would have been taken into consideration for 210 
the analysis.  For example, if a participant had a right eye with previously treated and inactive 211 
DME, this participant would have entered the DME pathway.  If there was a “recurrence” of 212 
DME in the right eye at the time of the EMERALD evaluation, the patient would have said to 213 
have “active DME”. Equally, if this same participant had “persistence” (i.e. never 214 
successfully treated prior to the EMERALD evaluation but active at the time of the visit) or 215 
“de novo” disease (active disease at the time of the EMERALD evaluation but never present 216 
before) in the left eye, the participant would have be n considered also to have “active” 217 
DME.  If this same participant did not have PDR in the right eye or left eye before (i.e. not 218 
eligible for the PDR pathway) but, at the time of the EMERALD study had “de novo” PDR in 219 
one eye, this participant would not have been included in main or sensitivity analyses for 220 
PDR but would have been included in the secondary analysis. The vice versa was also true 221 
for the DME main and sensitivity analyses, and correspondingly inclusion of “de novo” DME 222 










For all diagnostic accuracy analyses, the sensitivity, specificity, positive and negative 224 
likelihood ratios were calculated (with appropriate 95% confidence intervals (CIs) using 225 
Wilson’s method and diagt command in Stata respectiv ly). The difference in sensitivity and 226 
specificity between 7-field ETDRS and UWF images ases ed by the ophthalmic graders was 227 
compared with corresponding 95% CIs produced using Newcombe’s method for paired data34 228 
and McNemar’s test for the main analysis and sensitivity analysis 1.35 229 
All analyses were carried out using STATA V15 and without imputation of missing data.  230 
 231 
Health economic evaluation 232 
Resource use was captured on EMERALD case report forms (CRFs) at each participant’s 233 
EMERALD clinic visit, in order to compare costs of delivering the standard care pathway, 234 
ophthalmic grader pathway and the enhanced referenc standard. The cost analysis took the 235 
perspective of the NHS and personal social services and was estimated in UK pounds sterling 236 
using 2019/2020 prices.  Costs included staff costs, ba ed on the time and staff (including 237 
grade) required to obtain best-corrected visual acuity (BCVA), SD-OCT, 7-field and ultra-238 
wide field fundus images.  Costs included time and grade of the ophthalmologist evaluating 239 
the patient in the clinic, including undertaking slit-lamp biomicroscopy, review of the SD-240 
OCT images to assess DMO as well as the time invested counselling the patient. Times taken 241 
by graders to grade SD-OCT, and by graders and ophthalmologists (for the purpose of the 242 
enhanced reference standard) to grade 7-field and ultra-wide field fundus photographs were 243 
also obtained and costed.  Hourly wage rates for staff costs were obtained from the Unit 244 
Costs of Health and Social Care 2019. Other costs included the equipment required, 245 
overheads, and consumables. The equipment costs included acquisition and maintenance 246 
costs, considering the lifetime of the equipment and estimated throughput per year.  Data 247 










It was hypothesised the new pathway would have similar sensitivity as the standard care 249 
pathway but at lower cost, making the analysis a cost- nsequence one, including assessment 250 
of ophthalmologist time released by the new pathway. DME and PDR were assessed 251 
separately. Detailed methodology and results of the health economic evaluation will be 252 
published separately. 253 
Statistical Analysis and Health Economic Plans were agreed and made accessible on the 254 
EMERALD website (http://www.nictu.hscni.net/emerald-trial/#) prior to commencement 255 
data analysis.  Further methodological details of EMERALD can be found in the published 256 
protocol (https://bmjopen.bmj.com/content/9/6/e027795).36  EMERALD was executed and 257 
reported following STARD guidelines,37 and was prospectively registered (Clinicaltrials.gov-258 
NCT03490318; ISRCTN-10856638. 259 
 260 
Results 261 
Diagnostic Accuracy 262 
We recruited 397 participants of whom 272 were eligible with DME and 281 were eligible 263 
with PDR (Figure 1; supplemental tables 5 and 6).  Participants were recruited consecutively, 264 
whether they had active or inactive DME or PDR at the time of the EMERALD visit, with no 265 
case selection.34   We had planned to continue recruitment until we had achieved the 266 
minimum number of eligible participants for each group (104 individuals for each, active and 267 
inactive DME and PDR groups).  As participants could contribute to both the DME or PDR 268 
pathways, by February 8th 2019, we had recruited enough participants for three groups 269 
(active and inactive DME, and inactive PDR).  Peopl with previously successfully treated 270 
and active PDR seemed to be less frequently seen in clin cs and, thus, numbers recruited in 271 
this group had not reached the required number.  Thus, from February 8th 2019, when we had 272 










inactive DME, respectively), we decided to actively recruit people that had active PDR only 274 
and ask sites to actively pursue eligible participants for this group (e.g. recruiting from 275 
casualty, where these patients could present).  Consecutive potentially eligible participants 276 
with active PDR were then approached until recruitment for this group was also completed 277 
(and surpassed, as recruitment was not halted until all potentially eligible participants 278 
identified and approached for the active PDR group had been assessed). As participants could 279 
contribute for all other groups, as mentioned above, th n the number of eligible participants 280 
in all groups increased and was higher by the end of the study than that required based on 281 
sample size calculations.  282 
Demographics of participants are shown in Table 1. In total, 157 (40%) of 397 presented with 283 
severe disease (central-involving DME) in the DME group, 132 were eligible to the new 284 
pathway. In the PDR group, severe disease (PDR with pre-retinal or vitreous haemorrhage) 285 
was present in 77 (19%) of 397 participants, 75 were eligible to the new pathway.  286 
All participants except 34 (9%) had all images (i.e. SD-OCT, 7-field ETDRS and UWF 287 
images) obtained for testing the ophthalmic grader pathway on the same day as the reference 288 
standard. The great majority of eyes (92-97% of eyes, d pending on the imaging technology 289 
used) could be imaged and few images were ungradable (1% of SD-OCTs; 6% of 7-field 290 
ETDRS images; 5% of UWF images). Details for missing images are also summarised in 291 
supplementary Table 7).  292 
Under the main analysis, ophthalmic graders had sensitivity of 97% (142/147; 95% CI, 92-293 
99%) and specificity of 31% (35/113; 95% CI 23-40%) when compared with the reference 294 
standard, to detect DME (Table 2). Similar results were found when evaluating people with 295 
DME requiring further treatment, with central-involing DME, and when only referral for 296 
active DME was considered (i.e. excluding ‘unsure’ and ‘ungradable’) and when patients 297 









Under the main analysis, ophthalmic graders had lower sensitivity but higher specificity to 299 
detect PDR; both were similar (paired differences in ensitivity -3%, 95% CI (-14 – 8%), 300 
P=0·55; and specificity 5% (-5 to 16%), P=0·31) whether they used 7-field ETDRS 301 
(sensitivity 85%; 87/102, 95% CI 77-91%; specificity 48%; 77/160, 95% CI 41-56%) or 302 
UWF (sensitivity 83%; 87/105, 95% CI 75-89%; specificity 54%; 86/160, 95% CI 46-61%) 303 
images (Table 3). Results against the enhanced referenc  standard were similar to those 304 
against the reference standard (for 7-field ETDRS images, sensitivity of 82%; 111/135, 95% 305 
CI 75-88%; specificity 54%; 68/127, 95% CI 45-62%; for UWF images sensitivity 80%; 306 
110/138, 95% CI 72-86%; specificity 60%; 76/127, 95% CI 51-68%). Diagnostic accuracy 307 
results were similar to those of the main analysis when grading patients requiring further 308 
treatment (Table 3, supplementary tables 9-11). Sensitivity and specificity to detect more 309 
severe disease (PDR with sub-hyaloid and/or vitreous haemorrhage) appear to be slightly 310 
higher (not formally compared) when using UWF imaging (sensitivity 87%; 62/71, 95% CI 311 
78-93%; specificity 49%; 95/193, 95% CI 42-56%) instead of 7-field ETDRS (sensitivity 312 
80%; 53/66, 95% CI 69-88%; specificity 40%; 79/196, 5% CI 34-47%).  Findings were 313 
similar whether patients were assessed in NHS or resea ch clinics.  Sensitivity and specificity 314 
were lower when considering only referrals for active PDR (i.e. excluding ‘unsure’ and 315 
‘ungradable’) (Table 3).   316 
Results of post-hoc additional analyses for PDR and the secondary analyses are shown in 317 
Table 3 and supplementary Table 12. The additional a yses for PDR tended to have similar 318 
results or increased specificity with reduced sensitivity. Secondary analyses had very high 319 
sensitivity with low or very low specificity. 320 












Thirty-six participants attended focus groups organised in Northern Ireland (n=4), Scotland 324 
(n=2) and England (n=4). Participants voiced preference for face-to-face examinations by 325 
ophthalmologists, where information about their eyecondition could be received and 326 
discussed, where they would have the opportunity to ask questions and have anxieties 327 
assuaged.  In their absence, they wished immediate results from the grader’s assessment and 328 
maintaining periodic evaluations by ophthalmologists, even if at longer intervals. Participants 329 
were uncertain of professional identity, training and performance of photographers and 330 
graders. Graders and ophthalmologists supported the new pathway, but graders expressed 331 
caution about their ability to answer questions from patients unrelated to the activity of their 332 
disease.  333 
 334 
Cost-consequence analysis 335 
For DME, the cost-difference (savings) for the grader’s pathway would be £1390 per 100 336 
follow-up visits.  For PDR, the cost-difference (savings) for the grader’s pathway would be 337 
£461 for 7-field ETDRS images and £1889 for ultra-wide field images per 100 follow-up 338 
visits. The main driver of the difference in costs of imaging modalities for PDR was the time 339 
to obtain and read images (Supplementary table 13).  340 
Costs for the grader pathway take into account the specificity of the pathway (i.e. in each 100 341 
patients, a proportion of “false positives” will still need to be referred to the ophthalmologist, 342 
with the reference standard cost for ophthalmologist follow-up applied).  343 
 344 
Discussion 345 
The new ophthalmic grader pathway had high sensitivity to detect DME, of over 90% in all 346 
analyses, suggesting it would be safe to implement in clinical practice. The pathway had 347 










the ophthalmic grader pathway to detect high-risk PDR, with pre-retinal and/or vitreous 349 
haemorrhage, was higher (87%) when using ultra-wide field fundus images. It should be 350 
highlighted that the risk and consequences of a recur nce of PDR in eyes previously treated 351 
with PRP would not be expected to be as high and/or as severe, as if active disease were to 352 
occur in treatment naïve eyes. If a vitreous haemorrhage were to develop, patients would 353 
experience floaters and could be instructed to contact immediately ophthalmic clinics for 354 
timely evaluation. In most instances, the course of action would be observation until the 355 
haemorrhage clears, and then further PRP treatment, if required. With this in mind, the 356 
ophthalmic grader pathway for PDR would be considere  adequate and justifiable, especially 357 
in areas, and at times, where high demand of services prevents people with severe eye 358 
diseases accessing timely care. Given that UWF images had higher sensitivity to detect high-359 
risk PDR and were less costly than 7-field ETDRS, they may be preferred.  360 
The specificity of the new pathway to detect DME (31%) and PDR (54-60%) was not 361 
high.  The lower the specificity, the more “false positive” patients that have to be seen by the 362 
ophthalmologist. However even a poor specificity could provide useful savings in 363 
ophthalmologist time. It should be noted that, in EMERALD, images were evaluated without 364 
any information about patients (i.e. masked to any clinical data, including previous images). 365 
While this was a strength in scientific design, it is likely that if clinical information (e.g. 366 
location of previously identified new vessels) and previous images (e.g. SD-OCT scans of 367 
previously treated DME; images of new vessels following PRP treatment) were to be 368 
available, the sensitivity and specificity of the nw pathway would have been higher.  Indeed, 369 
if the new pathway is implemented in clinical practice, previous clinical information and 370 
images could be available to ophthalmic graders.   371 
The new ophthalmic grader pathway, if implemented appropriately, would help health 372 










subsequently, save sight.  The pathway, for example, could be implemented as a “one-stop” 374 
clinic, with images and image review being done at the same session and ophthalmic graders 375 
providing the results to patients immediately.  If ophthalmologists were to be running parallel 376 
clinics, they could provide advice to graders, if needed, in questionable cases, increasing the 377 
efficiency of the service and reducing the number of patients that would need to return for a 378 
further ophthalmologist assessment.  If planned adequat ly, it may be even possible to do 379 
treatments to active patients requiring them on the same visit (e.g. once these clinics have 380 
been running for some time it would be possible to determine the average number of patients 381 
requiring input from the ophthalmologist as well as those requiring treatment, and plan 382 
accordingly).  Patients with previously successfully treated and stable disease (DME, PDR, or 383 
both) could be pre-selected by ophthalmologists to go into the ophthalmic grader pathway.  384 
Based on EMERALD, patients could be moved to the grade ’s pathway as soon as further 385 
treatment for DME or PDR is not indicated.  Alternatively, ophthalmologists may decide, for 386 
example, to refer to the grader’s pathway patients with PDR with adequate laser PRP that 387 
have remained stable for a number of months already (e.g. 3-4 months); patients with DME 388 
that have received focal laser treatment and in whom DME has resolved; patients with DME 389 
that have received anti-VEGF therapy and who remained free of fluid for a certain period of 390 
time (e.g. 2-3 consecutive visits).  Based on the focus group work conducted in EMERALD 391 
and in order to ensure acceptability by patients of the new pathway, it would be important 392 
that, from time to time, patients that remain inactive are seen still by ophthalmologists. 393 
There is no clear view on what should be the minimal sensitivity and specificity 394 
acceptable for diagnostic or surveillance pathways. Figures of 80% for sensitivity and 95% 395 
for specificity have been quoted in many articles on screening for DR. These figures seem to 396 
have originated from a 1997 British Diabetic Association document, based on a consensus 397 









previously treated patients, in any case, is a rathe  different scenario and would pose 399 
different, known, risks, than DR screening, where people naïve to treatment are followed at 400 
less frequent intervals.   401 
In the future, it may be possible to use automatic image analysis, including artificial 402 
intelligence (AI), to determine presence of active DME/PDR on fundus images and SD-OCT 403 
scans. Recent studies demonstrated excellent sensitivity and specificity of AI methods to 404 
determine presence of referable DR (defined as presenc  of moderate and higher stages of 405 
non-proliferative DR, PDR or DME) in fundus images when compared with evaluation by 406 
retinal specialists.38,39 Indeed, an AI system (IDx-DR; IDx Technologies Inc, Coralville, IA, 407 
USA) has been developed and approved by the Food and Drug Administration (FDA) for the 408 
automated diagnosis of DR. However, studies on which this programme was developed 409 
included mostly treatment naïve patients and, thus, it remains to be elucidated if its diagnostic 410 
performance would be the same in the more complex group of previously treated patients 411 
who will have demonstrate alterations in retinal structure even when active disease is not 412 
present.   413 
The concept of what has been widely called ‘virtual clinics’ (evaluation of patients by 414 
looking at their images rather than through a face-to-face consultation in clinic) is not new. 415 
Published studies presented the experience of several groups using this form of evaluation for 416 
people with AMD40 and other medical retinal diseases, including diabet c retinopathy,41-44 417 
and glaucoma.45 These studies showed implementation of virtual clini s was feasible and 418 
reduced patient’s time in clinic, improving patient’s journey, and seemed to increase the 419 
efficiency of the service. Most studies, though, were based on the assessment of images by 420 
ophthalmologists, rather than allied non-medical stff, included newly referred patients, 421 










Very few studies evaluated the acceptability of virtual clinics to patients and health care 423 
professionals; these used questionnaires,44,46 and had low ascertainment (46-61%).44   424 
EMERALD findings may be of greatest relevance to countries with tax-funded health 425 
care systems, those having difficulties coping with health care demands, especially due to 426 
shortage of ophthalmologists, and in particular lowand middle-income countries (LMIC) and 427 
rural and underserved populations, interested in ide t fying more efficient and less costly 428 
health care strategies.  EMERALD could also serve as an example of using allied health care 429 
professionals to other areas of health care in ophthalmology and even outside this speciality.   430 
Strengths of EMERALD include its multicentre nature, strong methodology, adequate 431 
power and recruitment and lack of patient selection, making results more generalisable and 432 
applicable to routine care. Caveats include the fact that images of the iris and anterior 433 
chamber angle were not obtained for the evaluation of people with PDR. Although it would 434 
be very rare that new vessels would develop in these structures in eyes previously treated 435 
with laser PRP with no concomitant active NVE or NVD, if present, they would be missed.  436 
Additionally, fluorescein angiography was not undertaken as part of the study to determine 437 
activity of PDR.  It would be essential, if the new pathway is implemented, that 438 
recommendations from the focus group discussions were to be followed to ensure its 439 
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Figure 1. EMERALD flow diagram 
O-FTF = Ophthalmologist face-to-face clinical evaluation using slit-lamp biomicroscopy; 
SD-OCT = spectral domain optical coherence tomography; DME = diabetic macular oedema; 















Eligible for DME in 





Eligible for PDR in 




 n (%) n (%) n (%) n (%) n (%) 
Sex      
    Male 205 (65%) 175 (64%) 187 (65%) 185 (66%) 257 (65%) 
    Female 112 (35%) 97 (36%) 100 (35%) 96 (34%) 140 (35%) 
Age      
    18-59 135 (43%) 113 (42%) 151 (53%) 148 (53%) 188 (47%) 
    60 and over 182 (57%) 159 (58%) 136 (47%) 133 (47%) 209 (53%) 
Ethnic Origin      
    White 274 (86%) 240 (88%) 240 (84%) 234 (83%) 340 (86%) 
    Black 20 (6%) 17 (6%) 19 (7%) 19 (7%) 26 (7%) 
    Asian 16 (5%) 11 (4%) 20 (7%) 20 (7%) 22 (7%) 
    Middle Eastern 3 (1%) 1 (<1%) 5 (2%) 5 (2%) 5 (1%) 
    Other 4 (1%) 3 (1%) 3 (1%) 3 (1%) 4 (1%) 












SENA = sensitivity analysis; SD-OCT = spectral domain optical coherence tomography; DME = Diabetic 
macular edema. 
a
 grader referral for DME = “active” + “unsure” + “ungradable” 
 






for DME based on 
SD-OCT images  
 
Ophthalmologist face-to-face 
clinical evaluation using slit-
lamp biomicroscopy with the 
addition of SD-OCT scans to 
assess active DME in either eye
 
Sensitivity (%)  142/147 97% (92  ̶99%) 
Specificity (%) 35/113 31% (23  ̶40%) 
Positive likelihood ratio ·· 1·40 (1·23 ̶ 1·59) 
Negative likelihood ratio ·· 










clinical evaluation using slit-
lamp biomicroscopy with the 
addition of SD-OCT scans to 
assess active DME in either eye
 
Sensitivity (%) 139/146 95% (90  ̶98%) 
Specificity (%) 43/113 38% (30  ̶47%) 
Positive likelihood ratio ·· 1·54 (1·32 ̶ 1·78) 
Negative likelihood ratio ·· 




for DME based on 
SD-OCT images  
 
Ophthalmologist face-to-face 
clinical evaluation using slit-
lamp biomicroscopy with the 
addition of SD-OCT scans to 
assess active DME in either eye 
requiring treatment
 
Sensitivity (%) 81/85 95% (89  ̶98%) 
Specificity (%) 36/175 21% (15  ̶27%) 
Positive likelihood ratio ·· 1·20 (1·10 ̶ 1·31) 
Negative likelihood ratio ·· 











clinical evaluation using slit-
lamp biomicroscopy with the 
addition of SD-OCT scans to 
assess central involving active 
DME in either eye
 
Sensitivity (%) 121/129 94% (88  ̶97%) 
Specificity (%) 72/128 56% (48  ̶65%) 
Positive likelihood ratio ·· 2·14 (1·75 ̶ 2·62) 





for DME based on 




clinical evaluation using slit-
lamp biomicroscopy with the 
addition of SD-OCT scans to 
assess active DME in either eye 
in routine clinic
  
Sensitivity (%) 81/85 95% (89  ̶98%) 
Specificity (%) 26/65 40% (29  ̶52%) 
Positive likelihood ratio ·· 1·59 (1·30 ̶ 1·95) 








Table 3. Diagnostic performance of the ophthalmic grader pathway for the diagnosis of 
proliferative diabetic retinopathy 













lamp biomicroscopy to 
assess active PDR in 
either eye
 
Sensitivity (%) 87/105 83% (75  ̶89%) 
Specificity (%) 86/160 54% (46  ̶61%) 
Positive likelihood ratio ·· 1·79 (1·48 ̶ 2·16) 
Negative likelihood ratio ·· 0.32 (0·20 ̶ 0·50) 
Ophthalmic 
graders referral 







lamp biomicroscopy to 
assess active PDR in 
either eye 
Sensitivity (%) 87/102 85% (77  ̶91%) 
Specificity (%) 77/160 48% (41  ̶56%) 
Positive likelihood ratio ·· 1·64 (1·39 ̶ 1·95) 
Negative likelihood ratio ·· 0·31 (0·19 ̶ 0·50) 
SENA1 Ophthalmic 
graders identified 








lamp biomicroscopy to 
assess active PDR in 
either eye 
Sensitivity (%) 66/105 63% (53  ̶71%) 
Specificity (%) 116/159 73% (66  ̶79%) 
Positive likelihood ratio ·· 2·32 (1·73 ̶ 3·12) 
Negative likelihood ratio ·· 0·51 (0·39 ̶ 0·66) 
Ophthalmic 
graders identified 
active PDR based 






lamp biomicroscopy to 
assess active PDR in 
either eye 
Sensitivity (%) 70/99 71% (61  ̶79%) 
Specificity (%) 110/158 70% (62  ̶76%) 
Positive likelihood ratio ·· 2·33 (1·78 ̶ 3·04) 













lamp biomicroscopy to 
assess active PDR in 
either eye 
Sensitivity (%) 74/103 72% (62  ̶80%) 
Specificity (%) 137/159 86% (80  ̶91%) 
Positive likelihood ratio ·· 5·19 (3·46 ̶ 7·80) 











lamp biomicroscopy to 
assess active PDR in 
either eye 
Sensitivity (%) 65/98 66% (57  ̶75%) 
Specificity (%) 134/154 87% (81  ̶91%) 
Positive likelihood ratio ·· 5·11 (3·31 ̶ 7·87) 











lamp biomicroscopy to 
assess active PDR in 
either eye requiring 
treatment 
Sensitivity (%) 77/90 86% (77  ̶91%) 
Specificity (%) 91/175 52% (45  ̶59%) 
Positive likelihood ratio ·· 1.78 (1·49 ̶ 2·13) 
Negative likelihood ratio ·· 0.28 (0·16 ̶ 0·47) 
Ophthalmic 
graders referral 







lamp biomicroscopy to 
assess active PDR in 
Sensitivity (%) 74/84 88% (79  ̶93%) 
Specificity (%) 82/178 46% (39  ̶53%) 
Positive likelihood ratio ·· 1·63 (1·40 ̶ 1·91) 




















lamp biomicroscopy to 
assess active PDR with 
pre-retinal or vitreous 
haemorrhage in either 
eye
 
Sensitivity (%) 62/71 87% (78  ̶93%) 
Specificity (%) 95/193 49% (42  ̶56%) 
Positive likelihood ratio ·· 1·71 (1·45 ̶ 2·02) 
Negative likelihood ratio ·· 0·26 (0·14 ̶ 0·48) 
Ophthalmic 
graders referral 







lamp biomicroscopy to 
assess active PDR with 
pre-retinal or vitreous 
haemorrhage in either 
eye 
Sensitivity (%) 53/66 80% (69  ̶88%) 
Specificity (%) 79/196 40% (34  ̶47%) 
Positive likelihood ratio ·· 1·35 (1·14 ̶ 1·59) 












lamp biomicroscopy to 
assess active PDR with 
pre-retinal or vitreous 
haemorrhage in either 
eye
 
Sensitivity (%) 57/70 81% (71  ̶89%) 
Specificity (%) 153/192 80% (73  ̶85%) 
Positive likelihood ratio ·· 4·01 (2·96 ̶ 5·42) 











lamp biomicroscopy to 
assess active PDR with 
pre-retinal or vitreous 
haemorrhage in either 
eye 
Sensitivity (%) 42/64 66% (53  ̶76%) 
Specificity (%) 145/188 77% (71  ̶83%) 
Positive likelihood ratio ·· 2·87 (2·09 ̶ 3·94) 
Negative likelihood ratio ·· 0·45 (0·31 ̶ 0·63) 
SENA5 Ophthalmic 
graders referral 





Sensitivity (%) 110/138 80% (72  ̶86%) 
Specificity (%) 76/127 60% (51  ̶68%) 
Positive likelihood ratio ·· 1·98 (1·58 ̶ 2·49) 
Negative likelihood ratio ·· 0·34 (0·24 ̶ 0·49) 
Ophthalmic 
graders referral 






Sensitivity (%) 111/135 82% (75  ̶88%) 
Specificity (%) 68/127 54% (45  ̶62%) 
Positive likelihood ratio ·· 1·77 (1·45 ̶ 2·17) 










lamp biomicroscopy to 
assess active PDR in 
either eye plus 
Ophthalmologist 
Sensitivity (%) 101/125 81% (73  ̶87%) 
Specificity (%) 80/140 57% (49  ̶65%) 
Positive likelihood ratio ·· 1·89 (1·53 ̶ 2·32) 













active PDR in either eye 
based on ultra-wide 













lamp biomicroscopy to 
assess active PDR in 
either eye plus 
Ophthalmologist 
assessment identified 
active PDR in either eye 
based on 7-field ETDRS 
fundus images  
Sensitivity (%) 103/122 84% (77  ̶90%) 
Specificity (%) 73/140 52% (44  ̶60%) 
Positive likelihood ratio ·· 1·76 (1·46 ̶ 2·13) 




for PDR based on 
ultra-wide field 






lamp biomicroscopy to 
assess active PDR in 
either eye in routine 
clinic 
Sensitivity (%) 63/77 82% (72  ̶89%) 
Specificity (%) 47/92 51% (41  ̶61%) 
Positive likelihood ratio ·· 1·67 (1·32 ̶ 2·11) 
Negative likelihood ratio ·· 0·36 (0·21 ̶ 0·60) 
Ophthalmic 
graders referral 
for PDR based on 
7-field ETDRS 






lamp biomicroscopy to 
assess active PDR in 
either eye in routine 
clinic 
Sensitivity (%) 60/74 81% (71  ̶88%) 
Specificity (%) 41/91 45% (35  ̶55%) 
Positive likelihood ratio ·· 1·48 (1·19 ̶ 1·83) 
Negative likelihood ratio ·· 0·42 (0·25–0·71) 






















Multimodal retinal imaging assessed by trained non-medical staff had acceptable sensitivity 
for the detection of recurrent diabetic macular edema and proliferative diabetic retinopathy in 
previously treated and stable patients and saved resources. 
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